Skip to Content

Ono Pharmaceutical Co Ltd ADR OPHLY Stock Quote

| Rating as of

Morningstar‘s Stock Analysis OPHLY

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics OPHLY

Company Profile OPHLY

Business Description

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

8-2, Kyutaromachi 1-chome, Chuo-ku
Osaka, 541-8564, Japan
T +81 662635670
Industry Drug Manufacturers - General
Most Recent Earnings Jun 30, 2022
Fiscal Year End Mar 31, 2022
Employees 3,687